Anthrax Vaccine Stockpile Under Investigation By Sen. Grassley
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee chairman is requesting information on HHS' contract with VaxGen for its recombinant protective antigen anthrax vaccine and the Department's negotiation for procurement of existing anthrax vaccine. Grassley is concerned the current anthrax vaccine stockpile may be undersupplied.
You may also be interested in...
VaxGen Warning Letter Questions Anthrax Vaccine Promotions
CBER’s advertising branch cites VaxGen for promotions of its experimental anthrax vaccine, but the claims resemble those made in a 2004 HHS press release.
VaxGen Warning Letter Questions Anthrax Vaccine Promotions
CBER’s advertising branch cites VaxGen for promotions of its experimental anthrax vaccine, but the claims resemble those made in a 2004 HHS press release.
Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.